JW JoongWai Participates in JP Morgan Healthcare Conference

JW Choongwae Pharmaceutical CI (Provided by JW Choongwae Pharmaceutical)

[Asia Economy Reporter Chunhee Lee] JW Pharmaceutical announced on the 20th that it will participate in the '2022 JP Morgan Healthcare Conference,' held online for four days from the 10th of next month in San Francisco, USA, where it will introduce research projects and conduct one-on-one partnership consultations with overseas pharmaceutical companies and global investors via video conference.

Through this conference, JW Pharmaceutical plans to discuss technology licensing deals for its major innovative new drug candidates developed in-house. The gout treatment 'URC102' is being promoted for technology export targeting the global market excluding China. JW Pharmaceutical signed a technology transfer agreement for URC102 in the Chinese market with Simcere Pharmaceutical in China in 2019.

URC102 demonstrated high safety and excellent efficacy in the domestic Phase 2b clinical trial that ended last March. Based on this, JW Pharmaceutical intends to actively pursue technology export. The domestic Phase 3 clinical trial is scheduled to begin in the second half of next year, and recently, clinical trials have also started to expand the target to patients with renal impairment.

JW Pharmaceutical is also actively pursuing technology partnerships for the STAT3-targeting anticancer agent 'JW2286.' JW2286 works by inhibiting STAT3 and is indicated for solid tumors such as triple-negative breast cancer, gastric cancer, and colorectal cancer. Non-clinical trials and drug production research are currently underway. STAT3 is a protein that promotes the expression of various genes within cells. Abnormal activation of STAT3 causes cancer cell growth, proliferation, metastasis, and drug resistance, but no pharmaceutical company has yet succeeded in developing a new drug targeting STAT3.

In addition, JW Pharmaceutical will explain the latest research status and clinical development strategies for the hair loss treatment new drug candidate 'JW0061,' which activates the Wnt signaling pathway that regulates cell proliferation and regeneration to differentiate and promote cells involved in hair follicle stem cells and hair formation, and 'JW1601,' which is expanding indications from atopic dermatitis to ophthalmic diseases such as age-related macular degeneration and allergic conjunctivitis at this conference.

JW Pharmaceutical CEO Seong-Yeol Lee said, “We expect significant interest from overseas pharmaceutical companies and investors in JW’s core technologies and various innovative new drug candidates,” adding, “We will engage in diverse discussions to ensure that the R&D capabilities of JW, confirmed through the technology exports of JW1601 and URC102, lead to further achievements.”